946 results on '"Spillane, Andrew"'
Search Results
2. Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas
3. The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort
4. Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging
5. Clinical significance of intra-thoracic and intra-abdominal sentinel lymph nodes detected on lymphoscintigraphy in truncal melanoma patients
6. Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo
7. ASO Visual Abstract: Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas
8. Impact of an online risk prediction tool for sentinel node metastasis on clinical decision-making in melanoma care: A mixed methods study
9. ASO Author Reflections: Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas
10. ASO Visual Abstract: The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma: An Australian Cohort
11. ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging
12. Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach
13. Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study
14. Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma
15. Patient-reported health-related quality of life outcomes following mastectomy for breast cancer, with immediate, delayed or no breast reconstruction: Four-year follow-up from a prospective cohort study
16. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
17. Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
18. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.
19. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
20. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
21. Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous Melanoma
22. Patient and Staff Experiences of Embedding Electronic Patient Reported Outcome Measures for Distress Screening and Quality of Life Assessment, Into Routine Melanoma Care: A Mixed‐Methods Study.
23. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting
24. Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
25. Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting
26. Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework
27. A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).
28. ASO Visual Abstract: Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma
29. Histological regression in melanoma: impact on sentinel lymph node status and survival
30. Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies
31. Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma
32. Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management
33. Views of healthcare professionals about the role of active monitoring in the management of ductal carcinoma in situ (DCIS): Qualitative interview study
34. What are the appropriate thresholds for High Quality Performance Indicators for breast surgery in Australia and New Zealand?
35. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma
36. ASO Visual Abstract: Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-transit Melanoma Metastases
37. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
38. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator
39. Increasing access to breast reconstruction for women living in underserved non-metropolitan areas of Australia
40. Principles of patient-centred care and barriers to their implementation: a case study of breast reconstruction in Australia
41. Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
42. General practitioners are key to increasing Australia's low rate of breast reconstruction
43. Patient-reported outcomes with neoadjuvant vs adjuvant systemic therapy for operable breast cancer
44. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
45. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
46. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
47. Breast symptoms in adolescents and young adults presenting to a specialist breast clinic
48. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator
49. Current bi‐national attitudes towards targeted axillary dissection
50. Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.